A charitable access program for patients with lysosomal storage disorders in underserved communities worldwide.

Area of Science:

• Rare diseases
• Genetics
• Metabolic disorders

Background:

• Lysosomal storage disorders (LSDs) are rare genetic conditions with varied symptoms.
• Enzyme replacement therapy (ERT) and other treatments exist but face access challenges globally.
• Limited availability of approved drugs hinders treatment for patients in some regions.

Purpose of the Study:

• To evaluate the Takeda LSD Charitable Access Program's effectiveness.
• To assess the program's role in providing ERT to underserved patients.
• To explore sustainable healthcare solutions for rare metabolic diseases.

Main Methods:

• Donation of ERT to nonprofit organizations in selected countries.
• Support for medical capacity-building and independent grants for family support.
• Annual review of patient data by an independent Medical Expert Committee (MEC).

Main Results:

• 199 patients with Gaucher disease (GD), Fabry disease (FD), and Hunter syndrome (MPS II) enrolled from 13 countries.
• 147 out of 155 patients (95%) showed clinical improvements at 1-year follow-up.
• High follow-up response rate (>90%) confirmed widespread patient benefit.

Conclusions:

• The program successfully benefited patients unable to access essential treatments.
• High treatment efficacy was observed in the majority of patients.
• Innovative solutions are crucial to address global unmet needs for rare disease patients.